Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Current Deferred Revenue (2016 - 2020)

Historic Current Deferred Revenue for Aytu Biopharma (AYTU) over the last 6 years, with Q4 2020 value amounting to $475680.0.

  • Aytu Biopharma's Current Deferred Revenue changed N/A to $475680.0 in Q4 2020 from the same period last year, while for Dec 2020 it was $475680.0, marking a year-over-year change of. This contributed to the annual value of $339336.0 for FY2020, which is N/A changed from last year.
  • Aytu Biopharma's Current Deferred Revenue amounted to $475680.0 in Q4 2020.
  • Aytu Biopharma's 5-year Current Deferred Revenue high stood at $475680.0 for Q4 2020, and its period low was $1450.0 during Q2 2018.
  • Moreover, its 4-year median value for Current Deferred Revenue was $13990.0 (2018), whereas its average is $145070.9.
  • As far as peak fluctuations go, Aytu Biopharma's Current Deferred Revenue soared by 39700.17% in 2016, and later tumbled by 9843.36% in 2017.
  • Over the past 4 years, Aytu Biopharma's Current Deferred Revenue (Quarter) stood at $426000.0 in 2016, then plummeted by 98.88% to $4787.0 in 2017, then soared by 192.25% to $13990.0 in 2018, then surged by 3300.14% to $475680.0 in 2020.
  • Its Current Deferred Revenue stands at $475680.0 for Q4 2020, versus $232576.0 for Q3 2020 and $339336.0 for Q2 2020.